Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

Author's Avatar
Nov 09, 2022

%3Cb%3ELucid+Diagnostics+Inc.%3C%2Fb%3E (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of %3Cb%3EPAVmed+Inc.%3C%2Fb%3E (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the commencement of production of its EsoCheck® Esophageal Cell Collection Devices (“EsoCheck”) at Coastline International, Inc. (“Coastline”), a high-volume manufacturer headquartered in San Diego, CA with plants in Mexico. The Company has worked closely with Coastline over the past year to transfer the EsoCheck manufacturing lines from its prior low-volume manufacturer and to complete all the necessary validations to commence high-volume production at Coastline’s facility.